{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:10:34Z","timestamp":1780643434903,"version":"3.54.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Fatty liver index (FLI) calculated by using body mass index, waist circumference and levels of triglycerides and \u03b3-glutamyl transpeptidase is a noninvasive biomarker for diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), which is one of the high-risk conditions of atherosclerotic cardiovascular diseases. To compare the effects of pemafibrate and omega-3 fatty acid ethyl on FLI, we conducted a sub-analysis study of the Pemafibrate Reduction of triglyceride-rich lipoproteins compared with Omega-3 fatty acid ethyl for Unmet needs in Dyslipidemic patients on target to apoB-48 (PROUD48) study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>57 participants in the pemafibrate 0.4 mg per day treatment group (PEMA, men\/women: 37\/20, mean 64 years) and 60 participants in the omega-3 fatty acid ethyl 4 g per day treatment group (OMEGA-3, men\/women: 35\/25, mean 63 years) in the PROUD48 study were included in the present study. Changes in FLI and prevalence of MASLD from baseline to week 16 in PEMA and OMEGA-3 were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median FLI was significantly decreased by both PEMA (69.7 to 47.6, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and OMEGA-3 (64.8 to 59.5, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). There was a significant difference in change in FLI between PEMA and OMEGA-3 (-18.3 \u00b1 14.1 vs. -5.5 \u00b1 9.4, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). The proportions of MASLD estimated by FLI (baseline\/week 16) in PEMA and OMEGA-3 were 93.0\/68.4% (<jats:italic>P<\/jats:italic> = 0.002) and 90.0\/85.0% (<jats:italic>P<\/jats:italic> = 0.582), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pemafibrate is superior to omega-3 fatty acid ethyl in lowering effects of FLI and MASLD in patients with dyslipidemia receiving statin treatment, suggesting that pemafibrate is a beneficial agent for hypertriglyceridemia and reduction of the risk for MASLD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1549687","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:15:05Z","timestamp":1746072905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yasutaka","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Hiramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kumashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.68.7.60","article-title":"Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies","volume":"68","author":"Bainton","year":"1992","journal-title":"Br Heart J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.05.002","article-title":"Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control","volume":"106","author":"Carey","year":"2010","journal-title":"Am J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e061360","DOI":"10.1136\/bmjopen-2022-061360","article-title":"Study protocol of the PROUD48 study comparing the effects of pemafibrate and omega-3 fatty acid ethyl esters on apoB-48 in statin-treated patients with dyslipidaemia: A prospective, multicentre, open-label, randomised, parallel group trial in Japan","volume":"12","author":"Takeda","year":"2022","journal-title":"BMJ Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1094100","article-title":"The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)","volume":"10","author":"Takeda","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16552","article-title":"Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis","volume":"39","author":"Mori","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.2014.29.issue-12","article-title":"Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Otgonsuren","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.2014.40.issue-10","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0563","article-title":"Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population","volume":"69","author":"Takahashi","year":"2022","journal-title":"Endocr J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.v54.10","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Phaemacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.07.007","article-title":"Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease","volume":"181","author":"Jump","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02885.x","article-title":"Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study","volume":"23","author":"Capanni","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.6395","article-title":"Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia","volume":"14","author":"Zhu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.10.003","article-title":"Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease","volume":"40","author":"Spadaro","year":"2008","journal-title":"Dig Liver Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0870","article-title":"Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy","volume":"94","author":"Cussons","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial","volume":"62","author":"Argo","year":"2015","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0133496","DOI":"10.1371\/journal.pone.0133496","article-title":"Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin E2 in nonalcoholic fatty liver disease associated with hyperlipidemia: A randomized clinical trial","volume":"10","author":"Qin","year":"2015","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i22.7008","article-title":"Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis","volume":"21","author":"Li","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clin Nutr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/diagnostics11122316","article-title":"Pemafibrate ameliorates liver dysfunction and fatty liver in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: A retrospective study with the outcome after a mid-term follow-up","volume":"11","author":"Ikeda","year":"2021","journal-title":"Diagn (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6574-20","article-title":"Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: A retrospective, single-arm study","volume":"60","author":"Hatanaka","year":"2021","journal-title":"Intern Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score","volume":"5","author":"Hatanaka","year":"2021","journal-title":"JGH Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2020.99528","article-title":"Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease","volume":"6","author":"Shinozaki","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.106864","article-title":"Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study","volume":"7","author":"Shinozaki","year":"2021","journal-title":"Clin Exp Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5551\/jat.64896","article-title":"Comparison of efficacy between pemafibrate and omega-3-acid ethyl ester in the liver: the PORTRAIT study","volume":"31","author":"Sumida","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2022.07.010","article-title":"Impact of NAFLD and its pharmacotherapy on lipid profile and CVD","volume":"355","author":"Wang","year":"2022","journal-title":"Atherosclerosis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/metabo13050626","article-title":"Novel selective PPAR\u03b1 Modulator pemafibrate for dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis","volume":"13","author":"Yamashita","year":"2023","journal-title":"Metabolites"},{"key":"B40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-nutr-061021-030223","article-title":"Nonalcoholic fatty liver disease and omega-3 fatty acids: mechanisms and clinical use","volume":"43","author":"Spooner","year":"2023","journal-title":"Annu Rev Nutr"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.5551\/jat.10470","article-title":"Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia","volume":"18","author":"Masuda","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220630","article-title":"Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones","volume":"144","author":"Jalouli","year":"2003","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/biomedicines10112806","article-title":"Higher responsiveness for women, high transaminase levels, and fat percentage to pemafibrate treatment for NAFLD","volume":"10","author":"Iwadare","year":"2022","journal-title":"Biomedicines"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1549687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:15:06Z","timestamp":1746072906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1549687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":45,"alternative-id":["10.3389\/fendo.2025.1549687"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1549687","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1549687"}}